Arjan Bredenoord
Amsterdam UMC, University of Amsterdam
| Albert J (Arjan) Bredenoord (1977), MD is Consultant Gastroenterologist at the Amsterdam University Medical Centers and professor of Neurogastroenterology & Motility at the University of Amsterdam. After his Medicine studies in Antwerp, Belgium he worked on several clinical research projects on GI motility at the University of Utrecht, the Netherlands resulting in a PhD thesis on gastroesophageal reflux disease in 2006. His clinical training was performed in Nieuwegein, the Netherlands and at the Royal London Hospital in London, UK. He currently works as a consultant Gastroenterologist at the Amsterdam University Medical Centers where he is dedicated to patients care, scientific research and education in the field of benign esophageal diseases. Dr Bredenoord’s main focus is on achalasia, reflux disease and eosinophilic esophagitis. He is one of the pioneers of high-resolution manometry and impedance monitoring of the esophagus. The esophageal clinic in the AMC Amsterdam hosts the largest population of benign esophageal diseases in the Netherlands. Dr Bredenoord is an author of over 350 papers, books and book chapters and organizes regular courses in Europe, North America and Asia. Dr Bredenoord was President of the European Society of Eosinophilic Esophagitis EUREOS between 2017 and 2021 and president of the Dutch GI Motility society between 2014-2019, member of the Amsterdam UMC Institutional Review Board, UEG Scientific Committee, Dutch GI education committee and co-founder of the International HRM working group. |
Appearances
DateMay 8, 2023GERD refractory to standard therapy is a common problem in clinical practice. The causes are multiple and there is a need for a rational evidence based approach to this problem…Presenter
Amsterdam UMC, University of Amsterdam- DateMay 8, 2023GERD refractory to standard therapy is a common problem in clinical practice. The causes are multiple and there is a need for a rational evidence based approach to this problem…
Presenters
Amsterdam UMC, University of AmsterdamMcMaster UniversityUniversity of PennsylvaniaUniversity of California San Diego - DateMay 6, 2023This session will have six talks on the indications, limitations, procedural and technical aspects on clinically useful GI physiology tests. The attendees will learn for which patients these test can be of value, and what type of results you can expect and how reliable these are…
Presenter
Amsterdam UMC, University of Amsterdam - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenters
Speakers
Kaiser PermanenteUniversity of North Carolina School of MedicineAmsterdam UMC, University of AmsterdamMount Sinai School of MedicineNorthwestern University - The Feinberg School of Medicine - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenter
Amsterdam UMC, University of AmsterdamSpeakers
University of North Carolina School of Medicine - DateMay 9, 2023INTRODUCTION Interleukin-15 (IL-15) is an important cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses…
Presenter
Speakers
- DateMay 9, 2023BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
Presenter
Amsterdam UMC, University of AmsterdamSpeakers
University of North Carolina School of Medicine - DateMay 20, 2024BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
Presenter
University of North Carolina School of Medicine - DateMay 18, 2024
Presenter
Amsterdam UMC, University of Amsterdam - DateMay 18, 2024
Presenters
DateMay 20, 2024SOCIETY: AGA Pathophysiologic advances with management implications in eosinophilic esophagitisModerators
University of Colorado School of MedicineAmsterdam UMC, University of Amsterdam- DateMay 21, 2024BACKGROUND: Eosinophil infiltration is a hallmark of eosinophilic esophagitis (EoE). Histologic assessment of esophageal biopsies is required for diagnosis and evaluation of treatment effect. Current diagnostic criteria are based mainly upon a peak eosinophil count (PEC) ≥15…
Presenter
Speakers
Amsterdam UMC, University of AmsterdamUniversity of North Carolina School of Medicine - DateMay 21, 2024Interleukin-15 (IL-15) is a cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses. IL-15 expression has been shown to be dysregulated in eosinophilic esophagitis (EoE)…
Presenter
Amsterdam UMC, University of AmsterdamSpeakers
University of North Carolina School of Medicine - DateMay 18, 2024Endoscopic myotomy (POEM) was shown equally effective as laparoscopic Heller myotomy (LHM) in patients with achalasia at two years in a multicenter randomized trial. Postprocedural reflux esophagitis and treatment with acid inhibitors were more frequent after POEM…
Presenter
Speakers
Amsterdam UMC, University of AmsterdamUniversitatsklinikum Augsburg - DateMay 18, 2024Our previous pilot study showed that treatment with the histamine 1 receptor antagonist ebastine improved symptoms in patients with irritable bowel syndrome (IBS)…
Presenter
Speakers
Amsterdam UMC, University of Amsterdam - DateMay 18, 2024
Speaker
Amsterdam UMC, University of Amsterdam - DateMay 18, 2024
Speakers
